Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour.
Anastasia
A
Constantinidou
Robin L
RL
Jones
David
D
Olmos
Khin
K
Thway
Cyril
C
Fisher
Omar
O
Al-Muderis
Ian
I
Judson
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018218:Neoplasms, Fibrous Tissue / Q000188:drug therapy*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
D018943:Anthracyclines; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015251:Epirubicin; D003606:Dacarbazine; D004317:Doxorubicin; D007069:Ifosfamide